Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) Interest & Investment Income (2019 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed Interest & Investment Income for 7 consecutive years, with $5.9 million as the latest value for Q4 2025.

  • Quarterly Interest & Investment Income rose 30.76% to $5.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $21.9 million through Dec 2025, up 18.24% year-over-year, with the annual reading at $21.9 million for FY2025, 18.24% up from the prior year.
  • Interest & Investment Income hit $5.9 million in Q4 2025 for Harmony Biosciences Holdings, up from $5.7 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $20.0 million in Q4 2021 to a low of -$7.2 million in Q2 2021.
  • Historically, Interest & Investment Income has averaged $2.9 million across 5 years, with a median of $4.3 million in 2023.
  • Biggest five-year swings in Interest & Investment Income: surged 351.15% in 2021 and later crashed 73.07% in 2023.
  • Year by year, Interest & Investment Income stood at $20.0 million in 2021, then dropped by 23.97% to $15.2 million in 2022, then plummeted by 73.07% to $4.1 million in 2023, then rose by 9.3% to $4.5 million in 2024, then soared by 30.76% to $5.9 million in 2025.
  • Business Quant data shows Interest & Investment Income for HRMY at $5.9 million in Q4 2025, $5.7 million in Q3 2025, and $5.3 million in Q2 2025.